Molecular glue degraders: Lilly, AbbVie sign billion-dollar deals; BMS leads with three late-stage drugs

Data Compilation
#PharmaFlow

Pipeline Prospector March 2025: Trump’s FDA overhaul spooks biotech stocks; Roche, AbbVie, Novo ink obesity drug deals

Stock Recap
#PipelineProspector

Escitalopram Oxalate

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

91 API Suppliers, 30 USDMF, 21 CEP/COS, 11 JDMF, 23 EU WC, 30 KDMF, 20 NDC API, 37 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

1 Drugs in Development

1 Drugs in Development

INTERMEDIATES

26 Intermediate Suppliers

26 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

552 FDF Dossiers, 80 FDA Orange Book, 221 Europe, 52 Canada, 76 Australia, 41 South Africa, 82 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - EQ 10MG BASE, TABLET;ORAL - EQ 20MG BASE, TABLET;ORAL - EQ 5MG BASE, SOLUTION;ORAL - EQ 5MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

2 EUROAPI, 1 Minakem, 3 Rochem International Inc, 18 SPI Pharma, 7 DKSH, 6 Faran Shimi Pharmaceutical, 2 Boai NKY Pharmaceuticals Ltd, 6 Gangwal Healthcare, 7 Nanjing Well Pharmaceutical, 1 Pfanstiehl, 1 ACG Worldwide, 9 Actylis, 1 Aeon Procare, 7 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 21 BASF, 2 Clariant, 10 Corel Pharma Chem, 5 DFE Pharma, 2 Finar, 10 Gangwal Chemicals, 5 Ideal Cures Pvt Ltd, 4 Ingredion Pharma Solutions, 31 Kerry, 4 Kima Chemical, 6 Lonza Capsugel, 16 Microlex e.U, 1 Nanjing Bold Chemical, 2 Nomisma Healthcare, 2 Novo Excipients, 2 Pharmatrans-Sanaq, 7 Pluviaendo, 3 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 27 Roquette, 13 Seppic, 6 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 2 Shijiazhuang Huaxu Pharmaceutical, 11 Sigachi Industries, 3 The Dow Chemical Company, 1 Valens Pharmachem, 3 Vasa Pharmachem, 1 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

78 Fillers, Diluents & Binders, 50 Coating Systems & Additives, 31 Thickeners and Stabilizers, 30 Direct Compression, 29 Controlled & Modified Release, 28 Solubilizers, 24 Film Formers & Plasticizers, 23 Disintegrants & Superdisintegrants, 22 Granulation, 21 Parenteral, 19 Taste Masking, 18 Topical, 17 Chewable & Orodispersible Aids, 15 Co-Processed Excipients, 13 Lubricants & Glidants, 12 Rheology Modifiers, 8 Emulsifying Agents, 6 API Stability Enhancers, 5 Empty Capsules, 4 Vegetarian Capsules, 4 Surfactant & Foaming Agents, 4 Coloring Agents, 1 Soft Gelatin

DIGITAL CONTENT

9 News #PharmaBuzz

9 News #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions, 128 Regulatory FDF Prices, 13 Annual Reports

MARKET PLACE

11 APIs, 2 FDF Dossiers, 1 Intermediates

PATENTS & EXCLUSIVITIES

4 US Exclusivities

4 US Exclusivities

REF. STANDARDS & IMPURITIES

1 EDQM, 1 USP, 3 Others

$ Xls download

Filters

Last Updated on PharmaCompass	Virtual Booth	Country	Registrant Name	MF Registration No.	Classification	Initial Date of Reg.	Latest Date of Reg.	Registrant's Address
28/03/2025	H. Lundbeck AS	Denmark	H. Lundbeck A/S	222MF10216	Escitalopram oxalate	2010-08-10	2020-06-11	Ottiliavej 9, DK-2500, Valby, Copenhagen, Denmark
28/03/2025	Hetero Drugs	India	Hetero Labs Limited	303MF10125	Escitalopram oxalate	2021-08-16	2022-05-12	7-2-A2,Hetero Corporate,Industrial Estates Sanath Nagar,Hyderabad-500 018 Telangana INDIA

Escitalopram Oxalate

Escitalopram Oxalate

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

91 API Suppliers

30 USDMF

21 CEP/COS

11 JDMF

23 EU WC

30 KDMF

20 NDC API

37 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

1 Drugs in Development

INTERMEDIATES

26 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

552 FDF Dossiers

80 FDA Orange Book

221 Europe

52 Canada

76 Australia

41 South Africa

82 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - EQ 10MG BASE

TABLET;ORAL - EQ 20MG BASE

TABLET;ORAL - EQ 5MG BASE

SOLUTION;ORAL - EQ 5MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

2 EUROAPI

1 Minakem

3 Rochem International Inc

18 SPI Pharma

7 DKSH

6 Faran Shimi Pharmaceutical

2 Boai NKY Pharmaceuticals Ltd

6 Gangwal Healthcare

7 Nanjing Well Pharmaceutical

1 Pfanstiehl

1 ACG Worldwide

9 Actylis

1 Aeon Procare

7 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

21 BASF

2 Clariant

10 Corel Pharma Chem

5 DFE Pharma

2 Finar

10 Gangwal Chemicals

5 Ideal Cures Pvt Ltd

4 Ingredion Pharma Solutions

31 Kerry

4 Kima Chemical

6 Lonza Capsugel

16 Microlex e.U

1 Nanjing Bold Chemical

2 Nomisma Healthcare

2 Novo Excipients

2 Pharmatrans-Sanaq

7 Pluviaendo

3 Prachin Chemical

1 Qianhao Chemical (Hebei) Co., Ltd

1 Qualicaps

27 Roquette

13 Seppic

6 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

2 Shijiazhuang Huaxu Pharmaceutical

11 Sigachi Industries

3 The Dow Chemical Company

1 Valens Pharmachem

3 Vasa Pharmachem

1 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

78 Fillers, Diluents & Binders

50 Coating Systems & Additives

SOLUTION;ORAL - EQ 5MG BASE/5ML Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons